With an aging population and the increasing prevalence of orthopedic surgeries, postoperative infections in orthopedics have become a significant clinical challenge. Statistics indicate that musculoskeletal system infections account for 22% of all clinical infections, often accompanied by high mortality rates and extended hospital stays. While traditional treatments rely on systemic antibiotics, they are often limited in efficacy and may require secondary surgeries. To address this issue, a team led by Professor Chin-Chean Wong of the Orthopedics Department at Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare, has developed an innovative injectable and in situ-forming antibacterial hydrogel. This hydrogel solidifies in response to body temperature after implantation and releases antibiotics continuously, achieving precise localized treatment.
Technological Innovations and Advantages: Enhanced Treatment for Postoperative Infections
The hydrogel is composed of gelatin, hyaluronic acid, and genipin. Through precise formulation and cross-linking interactions, the hydrogel demonstrates excellent physicochemical properties in various environments. Its most notable feature is its temperature sensitivity—at 37°C (body temperature), the hydrogel rapidly solidifies and forms in situ, allowing precise localization at the surgical site. This property prevents it from being dispersed by bodily fluids and ensures stable drug release. Compared to traditional bone cement, the hydrogel’s drug release efficiency is 50 to 80 times higher, with prolonged release durations that achieve effective antibiotic concentrations.
Crucially, the hydrogel continuously releases antibiotics and strongly inhibits biofilm formation, which is essential for infection control in orthopedic surgeries. Its biodegradable nature eliminates the need for secondary surgery, as the material completely degrades and is absorbed without leaving harmful residues. Furthermore, the hydrogel can encapsulate growth factors and cells and can be precisely delivered to the affected site via guided injection, promoting localized bone repair and regeneration. Animal studies have confirmed its high biocompatibility, with no observed local or systemic toxic reactions during degradation, highlighting its immense clinical potential.
Expert Insights and Market Opportunities: Professor Chin-Chean Wong on Applications and Global Prospects
Professor Wong stated that this innovative technology significantly improves the treatment of postoperative infections in orthopedics while addressing multiple current clinical challenges. According to the 2022 AJRR report, the volume of joint replacement surgeries in the United States increased by 14%, with postoperative infections posing significant challenges to the medical field. Taiwan faces similar issues, and this injectable hydrogel can effectively control infections while reducing the need for secondary surgeries, offering vast application potential.
The technology has already been granted invention patents in Taiwan and the United States. Plans are underway to collaborate with medical device companies for rapid commercialization. Professor Wong emphasized that while the hydrogel is primarily designed for orthopedic applications, it can be extended to treat other clinical conditions, positioning it as a promising global product in the future healthcare market.
Resource: 可注射式抗菌性水膠 精準「針」對患部防感染
